Listing of Claims:

1. Use of an IFN-β therapeutic in the manufacture of a medicament for the treatment or prevention of glomerulonephritis in a mammal.

2. The use of claim 1, wherein glomerulonephritis is selected from the group consisting of focal glomeruloscerosis, collapsing glomerulopathies, minimal change disease, crescentic glomerulonephritis, nephritic syndrome, nephrotic syndrome, primary glomerulonephritis, secondary glomerulonephritis, proliferative glomerulonephritis, membraneous glomerulonephritis, membranoproliferative glomerulonephritis, immune-complex glomerulonephritis, anti-glomerular basement membrane (anti-GBM) glomerulonephritis, pauci-immune glomerulonephritis, diabetic glomerulopathy, chronic glomerulonephritis, and hereditary nephritis.

3. The use of claim 1 or 2, wherein the IFN-β therapeutic comprises mature IFN-β.

4. The use of any one of claims 1-3, wherein the IFN-β is human IFN-β.

5. The use of claim 4, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

6. The use of claim 4, wherein the IFN-β is IFN-β-1a.

7. The use of claim 4, wherein the IFN-β is IFN-β-1b.

8. The use of any one of claims 1-7, wherein the mammal is a human.

9. Use of an IFN-β therapeutic in the manufacture of a medicament for the treatment or prevention of chronic renal failure in a mammal.

10. The use of claim 9, wherein the IFN-β therapeutic comprises mature IFN-β.

11. The use of claim 9 or 10, wherein the IFN-β is human IFN-β.

12. The use of claim 11, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

13. The use of claim 11, wherein the IFN-β is IFN-β-1a.

14. The use of claim 11, wherein the IFN-β is IFN-β-1b.

15. The use of any one of claims 9-14, wherein the mammal is a human.

16. A method for treating glomerulonephritis in a mammal, comprising identifying a mammal having glomerulonephritis and administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.

17. The method of claim 16, wherein glomerulonephritis is selected from the group consisting of focal glomeruloscerosis, collapsing glomerulopathies, minimal change disease, crescentic glomerulonephritis, nephritic syndrome, nephrotic syndrome, primary glomerulonephritis, secondary glomerulonephritis, proliferative glomerulonephritis, membraneous glomerulonephritis, membranoproliferative glomerulonephritis, immune-complex glomerulonephritis, anti-glomerular basement membrane (anti-GBM) glomerulonephritis, pauci-immune glomerulonephritis, diabetic glomerulopathy, chronic glomerulonephritis, and hereditary nephritis.

18. The method of claim 16 or 17, wherein the IFN-β therapeutic comprises mature IFN-β.

19. The method of any one of claims 16-18, wherein the IFN-β is human IFN-β.

20. The method of claim 19, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

21. The method of claim 19, wherein the IFN-β is IFN-β-1a.

22. The method of claim 19, wherein the IFN-β is IFN-β-1b.

23. The method of any one of claims 16-22, wherein the mammal is a human.

24. A method for treating chronic renal failure in a mammal, comprising identifying a mammal having chronic renal failure and administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.

25. The method of claim 24, wherein the IFN-β therapeutic comprises mature IFN-β.

26. The method of claim 24 or 25, wherein the IFN-β is human IFN-β.

27. The method of claim 26, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

28. The method of claim 26, wherein the IFN-β is IFN-β-1a.

29. The method of claim 26, wherein the IFN-β is IFN-β-1b.

30. The method of any one of claims 24-29, wherein the mammal is a human.